References
Kirwan CJ, Lee T, Holt DW, Grounds RM, MacPhee IA, Philips BJ (2009) Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 35:1271–1275
Kirwan CJ, MacPhee IA, Lee T, Holt DW, Philips BJ (2012) Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med 38:76–84
Lin YS, Lockwood GF, Graham MA et al (2001) In vivo phenotyping for CYP3A by a single-point determination of midazolam plasma concentration. Pharmacogenetics 11:781–791
Frank D, Jaehde U, Fuhr U (2007) Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 63:321–333
Abdel-Rahman SM, Leeder JS, Wilson JT et al (2002) Concordance between tramadol and dextromethorphan parent/metabolite ratios: the influence of CYP2D6 and non-CYP2D6 pathways on biotransformation. J Clin Pharmacol 42:24–29
Acknowledgments
We are grateful for the support of an ESICM/ECCRN Basic Sciences Award to Dr. Lane for this research.
Conflicts of interest
On behalf of all authors, the corresponding author states that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lane, K., Dixon, J.J., McKeown, D. et al. Using tramadol to measure CYP2D6 metabolism in critically ill adults. Intensive Care Med 40, 1177–1178 (2014). https://doi.org/10.1007/s00134-014-3372-y
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00134-014-3372-y